Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
Zebras and giraffes offer one another protection without food competition.
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.